Infinimmune and Merck Sign Antibody Discovery Agreement

Infinimmune and Merck (MRK) have signed an agreement to collaborate on antibody discovery. Under the terms of the deal, Infinimmune's proprietary technology will be used to develop novel antibodies against Merck's selected biological targets. While financial details of the agreement were not disclosed, Infinimmune is expected to receive upfront payments, research funding, and success-based milestone payments. Additionally, royalties on commercialized products are part of the agreement. Merck aims to expand its antibody-based therapeutic portfolio through this collaboration, while Infinimmune gains an opportunity to validate its technology with a major pharmaceutical company. This is not investment advice.

📊 MRK — Piyasa Yorumu

▲ up · 70%

The antibody discovery agreement with Infinimmune is being regarded as a positive development for MRK. A 2.3% rise in the last 24 hours, coupled with the MACD remaining above its signal line, supports a short‑term upward momentum for the stock. With an RSI of 57, the shares are not in an overbought zone, suggesting the rally could be sustainable. The stock is trading above both the 20‑ and 50‑day moving averages, indicating a technically supported uptrend. Analysts anticipate a price pullback to the 115‑117 range within 1–3 days, though volatility is expected to remain elevated.

RSI 14

57.1

MACD

0.57

24h Δ

2.30%

Canlı Grafikler